What is the current stock price of NRx Pharmaceuticals, Inc. (NRXP)?

As of the latest market data, NRx Pharmaceuticals, Inc. (NRXP) is trading at $2.22. The stock has seen a loss of -1.77% today.

Does NRx Pharmaceuticals, Inc. (NRXP) pay a dividend?

Based on current data, NRx Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of NRx Pharmaceuticals, Inc.?

The current market capitalization of NRx Pharmaceuticals, Inc. (NRXP) is approximately unavailable.

NRXP

NRx Pharmaceuticals, Inc.·Healthcare

2.22

1.770%(−0.04)

Market Closed

2.32

4.505%(+0.10)

After Hours

Last Updated: — ET

52W L: $1.6252W H: $3.84

NRXP NEWS

globenewswire.com

5d ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory review.

globenewswire.com

Mar 30

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

SARASOTA, Fla. and PARIS, March 30, 2026 (GLOBE NEWSWIRE) -- Hope Therapeutics, Inc. (“Hope”), a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced a strategic partnership with Emobot Health to deploy its revolutionary AI-driven emotional monitoring platform across Hope's rapidly expanding network of interventional psychiatry clinics. This roll-out represents the first large-scale clinical integration of Emobot's "Depression Thermometer," a passive monitoring tool designed to detect early treatment response and prevent relapse in patients with Treatment-Resistant Depression (TRD).

seekingalpha.com

Mar 24

NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 24

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth.

zacks.com

Mar 23

NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.3 per share a year ago.

seekingalpha.com

Mar 23

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

Company Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-12-04

Beta

1.83

Websitewww.nrxpharma.com↗